Bendamustine (Treanda) for chronic lymphocytic leukemia: A brief overview

P and T

Volumn 34, Issue 2, 2009, Pages 73-76

  Leong, Hoyee ^a   Bonk, Mary Ellen ^b  

^a Drug Information and Technology Assessment

^b University HealthSystem Consortium   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ALOPRIM; BENDAMUSTINE; CHLORAMBUCIL; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; FLUDARABINE PHOSPHATE; FLUVOXAMINE MALEATE; MITOXANTRONE; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE SULFATE;

ANEMIA; ASTHENIA; BREAST CANCER; CHILL; CHRONIC LYMPHATIC LEUKEMIA; COUGHING; DIARRHEA; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; FATIGUE; FEVER; FOLLICULAR LYMPHOMA; HUMAN; HYPERSENSITIVITY; HYPERURICEMIA; INFECTION; LEUKOPENIA; LUNG SMALL CELL CANCER; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PNEUMONIA; RASH; RHINOPHARYNGITIS; SEPSIS; SHORT SURVEY; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME; VOMITING; WEIGHT REDUCTION;

EID: 62149090684     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (27)

1. American Cancer Society. Detailed guide: leukemia-chronic lymphocytic (CLL): What are the key statistics about chronic lymphocytic leukemia? Available at: www.cancer.org. Accessed October 2008.
2. Bergmann MA, Goebeler ME, Herold M, et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase I/II study of the German CLL Study Group. Haematologica 2005;90 (10): 1357-1364.
3. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximabrefractory indolent and transformed non- Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study. J Clin Oncol 2008;26(2):204-210.
4. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005;23(15):3383-3389.
5. Knop S, Straka C, Haen M, et al. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005; 90 (9): 1287-1288.
6. Pönisch W, Rozanski M, Goldschmidt H, et al. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: Results of a phase I clinical trial. Br J Haematol 2008;143 (2): 191-200.
7. von Minckwitz G, Chernozemsky I, Sirakova L, et al. Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): A phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate, and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) as first-line treatment of MBC. Anticancer Drugs 2005; 16(8):871-877.
8. Koster W, Stamatis G, Heider A, et al. Carboplatin in combination with bendamustine in previously untreated patients with extensive-stage small cell lung cancer (SCLC). Clin Drug Invest 2004; 24(10):611-618.
9. Schmittel A, Knodler M, Hortig P, et al. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung Cancer 2007;55 (1): 109-113.
10. Hartmann JT, Mayer F, Schleicher J, et al. Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: A noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001). Cancer 2007;110(4):861-866.
11. Rasschaert M, Schrijvers D, Van den Brande J, et al. A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors. Anticancer Drugs 2007;18(5): 587-595.
12. National Comprehensive Cancer Network. NCCN updates non-Hodgkin's lymphoma guidelines, April 22, 2008. Available at: www.nccn.org/about/news/ newsinfo.asp?NewsID=136. Accessed October 2008.
13. Cephalon receives FDA approval for Treanda, a novel chemotherapy for chronic lymphocytic leukemia, March 20, 2008. Available at: www.cephalon.com. Accessed October 2008.
14. Cephalon receives FDA approval for Treanda to treat patients with relapsed, indolent non-Hodgkin's lymphoma, October 31, 2008. Available at: www.cephalon.com. Accessed December 3, 2008.
15. Center for Drug Evaluation and Research. Application No. NDA 22-249. Medical review(s), part 1. Available at: www.fda.gov/cder/foi/nda/2008/ 22249s000-SumR.pdf. Accessed September 2008.
16. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008; 14(1): 309-317.
17. Treanda (bendamustine hydrochloride) for injection, for intravenous infusion, prescribing information. Celphalon, revised March 2008. Available at: www.cephalon.com/fileadmin/newsroom/assets/Treanda-pi.pdf. Accessed September 2008.
18. Balfour JA, Goa KL. Bendamustine. Drugs 2001;61(5):631-638; discussion, 639-640.
19. Knauf WU, Lissichkov T, Aldaoud A, et al. Bendamustine versus chlorambucil in treatment-naive patients with B-cell chronic lymphocyctic leukemia (B-CLL): Results of an international phase III study (Abstract 2043). Blood 2007;110:609a.
20. Koppler H, Heymanns J, Pandorf A, et al. Bendamustine plus mitoxantrone: A new effective treatment for advanced chronic lymphocytic leukaemia. Results of a phase I/II study. Leuk Lymphoma 2004; 45 (5) =911-913.
21. LissitchkovT, Arnaudov G, Peytchev D, et al. Phase I/II study to evaluate dose-limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HC1 in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol 2006; 132 (2) =99-104.
22. Herold M, Schulze A, Niederwieser 1), et al. Bendamustine, vincristine, and prednisone (BOP) versus cyclophosphamide, vincristine, and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: Results of a randomised phase III trial (OSHO No. 19). J Cancer Res Clin Oncol 2006; 132 (2): 105-112.
23. Weide R, Heymanns J, Gores A, et al. Bendamustine mitoxantrone and rituximab (BMR): A new effective regimen for refractory or relapsed indolent lymphomas. Leuk Lvmphoma 2002;43(2): 327-331.
24. Weide R, Pandorf A, Heymanns J, et al. Bendamustine/mitoxantrone/ rituximab (BMR): A very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk Lymphoma 2004;45(12): 2445-2449.
25. Koenigsmann M, Knauf W, Herold M. et al. Fludarabine and bendamustine in refractory and relapsed indolent lymphoma: A multicenter phase I/II trial of the East German Society of Hematology and Oncology (OSHO). Leuk Lymphoma 2004;45(9):1821-1827.
26. Center for Drug Evaluation and Research. Application No. NDA 22-249. Medical review(s), part 2. Available at: www.fda.gov/cder/foi/nda/2008/ 22249s000-SumR.pdf. Accessed September 2008.
27. Murray L. Red Book: Pharmacy's Fundamental Reference. Montvale, NJ: Thomson PDR; 2008.